Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection

Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection Ahmedabad, India, 18 April, 2022 Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) has received final approval from the USFDA to market Cyanocobalamin Injection in the strengths of 1,000 mcg/mL,10,000 mcg/10 mL (1,000 mcg/mL), and 30,000 mcg/30 mL (1,000 mcg/mL) Multiple -Dose Vials. (US RLD: Cyanocobalamin). Cyanocobala min injection is used to treat and prevent lack of vi tamin B12 that may be caused due to pernicious anemia (lack of a natural substance needed to absorb vitamin B12 from the intestine), certain diseases, infections or medications decrease the amount of vitamin B12 absorbed from food. The drug will be manufactured at the group’s injectables manufacturing facility at Jarod, Gujarat. The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of h ealthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life - sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com ***

The release as fetched from its publisher. zyduslife.com ↗